Personalized medication withdrawal for children with inactive JIA
Part of Bones, joints & muscles, Immune system & allergy, Skin clinical trials.
This study looks at whether it is safe to stop or reduce arthritis medication in children with juvenile idiopathic arthritis (JIA) whose disease has been inactive for at least 6 months. The goal is to find a personalized approach to help each child when their medication is no longer needed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child must have been diagnosed with juvenile idiopathic arthritis (JIA).
- Your child's arthritis must be inactive (no symptoms) for at least 6 months while still on medication.
- Your child is currently taking a disease-modifying antirheumatic drug (DMARD) like methotrexate, a biologic, or a targeted synthetic treatment.
- Your child does not have systemic JIA or undifferentiated arthritis.
- Your child does not have severe eye inflammation (uveitis) that requires treatment with pills or injections.
- Your child has not had a previous attempt to taper or stop their arthritis medication that failed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if removing certain foods can improve arthritis symptoms in children aged 6 to 17. It may be an option if current medicines are not working well or if you want to explore dietary changes.
This study follows people with rheumatoid arthritis (RA) who have achieved remission—meaning their disease is well-controlled—to see how safely doctors can reduce or stop their medications over time. You would be monitored regularly to ensure your RA stays in remission.
This trial tests whether children with juvenile idiopathic arthritis (JIA) who have been doing well for over a year can safely reduce their medications. The goal is to find the best way to keep arthritis under control while avoiding unnecessary treatments.
This study creates a personalized medicine network to better understand and treat childhood arthritis. If you have JIA or unexplained joint inflammation, researchers will look at your biology to find the best treatment approach for you.
This Phase 3 study tests whether children with early juvenile idiopathic arthritis do better by starting with one treatment approach and adjusting (stepping up or stepping down) based on how their arthritis responds. It may help find the safest, most effective long-term plan for controlling symptoms with fewer side effects.
This study tests different medication sequences for children and teens with polyarticular juvenile idiopathic arthritis (JIA) who still have moderate or high disease activity after at least 3 months on their first tumor necrosis factor inhibitor (TNFi) therapy. The goal is to find the best next step to control symptoms and improve quality of life.
Hear when a new Juvenile Idiopathic Arthritis (JIA) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.